NSE · AMANTA
Amanta Healthcare Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹276 Cr with net profit ₹11 Cr — a 3.8% net margin, versus 1.29% the period before.
Shareholding
As of 2026-06-30
- Promoter63.8%
- Public22.85%
- FII0.43%
- DII12.92%
12,612 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.05× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 2. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Drug Manufacturers - Specialty & Generic · ranked #1 of 15 by market cap · medians across 5 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Procter & Gamble Health Limited | ₹10,981 Cr | 116.08 | 20.94 | 62.32% | 23.22% |
| Medico Remedies Limited | ₹384 Cr | 65.15 | 5.06 | 17.38% | 6.36% |
| Par Drugs & Chemicals Ltd. | ₹118 Cr | 138.9 | 1.05 | 11.71% | 12.65% |
| Krebs Biochemicals & Industries Ltd. | ₹117 Cr | — | — | 10.4% | -71.34% |
| Ortin Global Limited | ₹12 Cr | — | 9.95 | -59.85% | -822.22% |
| Amanta Healthcare Limited(this company) | — | 100.73 | 2.86 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashAmanta Healthcare Limited, listed as AMANTA, has a market capitalization of Rs 639 Cr. For the financial year ending March 2025, the company reported a revenue of Rs 276.09 Cr and a profit margin of 5.17%. The earnings per share (EPS) for the same period was Rs 4.23, with a return on equity (ROE) of 7.46% and a return on capital employed (ROCE) of 9.58%.
Positives
- +Promoter shareholding has increased from 63.56% in December 2025 to 63.80% in June 2026.
- +The company reported a net profit of Rs 10.50 Cr in March 2025, a significant increase from Rs 3.63 Cr in March 2024.
- +Return on Capital Employed (ROCE) improved to 9.58% in March 2025 from 1.55% in March 2024.
Negatives
- −The company's PE ratio is high at 102.26.
- −The debt-to-equity ratio is 2.12, which is comparatively high.
- −FII shareholding decreased from 1.09% in December 2025 to 0.43% in June 2026.
- −The company is under ESM 2 surveillance, indicating increased regulatory scrutiny.
- −Net profit in December 2025 was Rs 4.63 Cr, decreasing to Rs 1.21 Cr in September 2025 before recovering.
Financial Performance
Amanta Healthcare Limited's revenue has shown fluctuations over the past few years, reaching Rs 276.09 Cr in March 2025. Net profit for March 2025 was Rs 10.50 Cr, marking a recovery from a net loss of Rs 2.11 Cr in March 2023. Quarterly revenue for March 2026 was Rs 76.99 Cr, with a net profit of Rs 5.53 Cr.
Profitability & Returns
The company reported an EPS of Rs 4.23 for the latest financial year. The profit margin stands at 5.17%. Return on Equity (ROE) was 7.46% and Return on Capital Employed (ROCE) was 9.58% in the latest annual reporting period. However, the company's PE ratio is 102.26.
Balance Sheet
Amanta Healthcare Limited has a book value of Rs 56.71. The debt-to-equity ratio is 2.12, indicating a leverage position. Further details regarding assets and liabilities are not provided in the available data.
Ownership & Pledges
As of June 30, 2026, promoters held 63.80% of the shares. DIIs held 12.92% and FIIs held 0.43% of the company's shares. Public shareholding was 22.85%. There are no reported promoter share pledges as of June 30, 2026.
Regulatory & Surveillance
Amanta Healthcare Limited is under ESM (Enhanced Surveillance Measure), specifically 'ESM 2', as indicated by its surveillance status. This involves certain surveillance measures implemented by the exchanges.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.